Quality Improvement Pilot
Facilitation of Cancer Prevention and Screening Guideline Implementation: Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University Of Kentucky
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Normal Volunteers
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Interventional Arm
Intervention
|
The practice facilitation intervention (implementation strategy package) consists of QI projects designed for primary care providers with external practice facilitation and technical support provided by a QI Coach and Data Coach on our team. The QI projects focus on the implementation of cancer prevention and early detection guidelines in primary care settings, specifically one QI project for each of the following clinical guidelines: colorectal cancer screening, lung cancer screening, and tobacco treatment. The study participants are the healthcare providers and staff, not the patients, since the goal of the practice facilitation intervention (implementation strategy package) is to improve the implementation of existing standard of care. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Colorectal Cancer: Screening Rate (Patient Population)
Time Frame: 6 months
|
Percent of patients age 50-75 who completed appropriate screening for colorectal cancer.
|
6 months
|
|
Lung Cancer: Screening Rate (Patient Population)
Time Frame: 6 months
|
Percent of eligible patients with shared decision-making visit AND completed baseline LDCT scan.
|
6 months
|
|
Tobacco: Treatment Rate (Patient Population)
Time Frame: 6 months
|
Percent of patients identified as tobacco user who received tobacco cessation intervention.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Pamela C Hull, PhD, University Of Kentucky
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 77178
- 3P30CA177558-08S3 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.